ABILIFY
Total Payments
$376,319
Transactions
537
Doctors
458
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $876.67 | 31 | 30 |
| 2023 | $4,027 | 124 | 88 |
| 2022 | $1,399 | 69 | 66 |
| 2021 | $4,181 | 3 | 2 |
| 2020 | $4,419 | 252 | 249 |
| 2019 | $351,359 | 51 | 25 |
| 2018 | $5,000 | 1 | 0 |
| 2017 | $5,058 | 6 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $344,006 | 24 | 91.4% |
| Education | $10,485 | 481 | 2.8% |
| Consulting Fee | $10,400 | 1 | 2.8% |
| Royalty or License | $10,000 | 2 | 2.7% |
| Travel and Lodging | $745.82 | 5 | 0.2% |
| Food and Beverage | $682.10 | 24 | 0.2% |
Payments by Type
Research
$344,006
24 transactions
General
$32,313
513 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $336,381 | 2 |
| A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM (IE, MAINTENANCE) EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $4,143 | 0 |
| A PHASE 1, OPEN-LABEL, PARALLEL ARM TRIAL TO DETERMINE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF SINGLE DOSES OF ARIPIPRAZOLE INTRAMUSCULAR DEPOT ADMINISTERED GLUTEALLY IN ADULT SUBJECTS WITH SCHIZOPHRENIA | Otsuka Pharmaceutical Development & Commercialization, Inc. | $3,483 | 0 |
Top Doctors Receiving Payments for ABILIFY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Portland, OR | $274,279 | 25 |
| , MD | General Practice | Rochester, NY | $79,662 | 1 |
| Daniel Friedland | — | San Diego, CA | $10,881 | 5 |
| , M.D | Cardiovascular Disease | Dana Point, CA | $334.72 | 6 |
| , M.D | Cardiovascular Disease | Placentia, CA | $323.18 | 6 |
| , MD | Health Educator | Philadelphia, PA | $264.66 | 1 |
| , M.D | Family Medicine | Temecula, CA | $245.36 | 4 |
| , M.D | Cardiovascular Disease | Placentia, CA | $212.04 | 4 |
| , MD | Interventional Cardiology | Costa Mesa, CA | $212.04 | 4 |
| , M.D | Interventional Cardiology | Costa Mesa, CA | $200.50 | 4 |
| , MD | Cardiovascular Disease | Murrieta, CA | $150.64 | 4 |
| , DO | Cardiovascular Disease | Costa Mesa, CA | $122.68 | 2 |
| , M.D | Internal Medicine | San Clemente, CA | $122.68 | 2 |
| , M.D., PH.D | Internal Medicine | Placentia, CA | $122.68 | 2 |
| , MD | Clinical Neurophysiology | Gilbert, AZ | $116.65 | 1 |
| , MD | Neurology | Phoenix, AZ | $116.65 | 1 |
| , M.D | Neurology | Phoenix, AZ | $116.65 | 1 |
| , MD | Interventional Cardiology | Aliso Viejo, CA | $89.36 | 2 |
| , MD | Cardiovascular Disease | Murrieta, CA | $89.36 | 2 |
| , MD | Cardiovascular Disease | Ladera Ranch, CA | $87.84 | 2 |
| , M.D | Psychiatry | Paterson, NJ | $85.04 | 1 |
| , MD | Cardiovascular Disease | Laguna Hills, CA | $77.82 | 2 |
| , MD | Internal Medicine | Mission Viejo, CA | $77.82 | 2 |
| , M.D | Family Medicine | Hemet, CA | $77.82 | 2 |
| , MD | Cardiovascular Disease | Anaheim, CA | $77.82 | 2 |
Ad
Manufacturing Companies
- Otsuka Pharmaceutical Development & Commercialization, Inc. $355,010
- E.R. Squibb & Sons, L.L.C. $10,456
- Otsuka Pharmaceutical Co., Ltd. $10,265
- Celgene Corporation $349.95
- Otsuka America Pharmaceutical, Inc. $238.45
Product Information
- Type Drug
- Total Payments $376,319
- Total Doctors 458
- Transactions 537
About ABILIFY
ABILIFY is a drug associated with $376,319 in payments to 458 healthcare providers, recorded across 537 transactions in the CMS Open Payments database. The primary manufacturer is Otsuka Pharmaceutical Development & Commercialization, Inc..
Payment data is available from 2017 to 2024. In 2024, $876.67 was paid across 31 transactions to 30 doctors.
The most common payment nature for ABILIFY is "Unspecified" ($344,006, 91.4% of total).
ABILIFY is associated with 3 research studies, including "A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM IE, MAINTENANCE EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER" ($336,381).